Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar
Executive Summary
Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist
You may also be interested in...
Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs
Bristol Myers-Squibb's sales agreement with Ventiv for the promotion of the antibiotics Cefzil and Tequin may be a new model for using contract sales organizations in an environment of downsizing
Merck To Sign 50 Business Development Deals In 2005
Merck's goal is to sign about 50 business development deals in 2005, the same level as 2004, the company said
Bristol Outsourcing Of Cefzil, Tequin To Ventiv May Be New Model For CSOs
Bristol Myers-Squibb's sales agreement with Ventiv for the promotion of the antibiotics Cefzil and Tequin may be a new model for using contract sales organizations in an environment of downsizing